Telisotuzumab vedotin (Teliso-V) links the c-MET antibody with MMAE and was evaluated in the phase 2 trial, LUMINOSITY, in previously treated NSCLC patients with elevated c-MET expression (intermediate defined as 25–50%, high > 50%). Here, MET is linked to non-small cell lung carcinoma.